Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.
mikeelogan

Research And Markets: Global Psoriasis Pipeline Highlights Report 2014-2017 - Yahoo Finance

CME Outfitters? Two-Part Medical Simulation on Psoriasis Featuring Expert Faculty Commentary Now Available Online

Psoriasis Pipeline by Drug Class 3. Psoriasis Pipeline by Company 4. Psoriasis Phase 3 Clinical Trial Insights 5. Psoriasis Phase 2 Clinical Trial Insights 6. Psoriasis Phase 1 Clinical Trial Insights 7. Psoriasis Preclinical Research Insights 8.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/research-markets-global-psoriasis-pipeline-104300215.html

It was created to address important healthcare and wellness needs via breakthrough solutions, all centered around the "well-being of the body and mind". Wellness Center USA, Inc. is the parent company of three businesses reporting consolidated: Stealth Mark , National Pain Centers , and Psoria-Shield . About The Medical Alliance, Inc. The Medical Alliance (TMA) ( http://themedalliance.com ) represents the 2013 merger of The ComedIT Group, Ocean Medical, and TFGI; combining over 75 years experience in delivering integrated consulting services to manufacturers, distributors, and candidates in the medical device, supply, and information technology arenas. TMA has offices in Amsterdam, the Netherlands, Utica, NY, Coconut Grove, FL and Jacksonville, FL.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/psoria-shield-inc-reports-successful-134000470.html

Biofrontera AG: Biofrontera significantly increases its turnover in Germany in 2014 - Yahoo Finance

Outlook 2015: moving forward with the approval process, increasing turnover Biofrontera will continue to pursue its two most important objectives: the approval of Ameluz to treat actinic keratosis in the USA and the extension of the indications to include basal cell carcinoma in Europe. We are currently compiling the dossier with all the study results for the FDA and want to submit this during the second quarter of otc psoriasis treatment 2015. About one year is then expected to be required to be granted approval.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/biofrontera-ag-biofrontera-significantly-increases-060202614.html

Psoria-Shield, Inc. Reports Successful Exhibition at the American Academy of Dermatology's 73rd Annual Meeting - Yahoo Finance

Armstrong, MD, MPH, and Alan Menter, MD guide you through the simulations to improve your knowledge base and clinical management skills in patients with psoriasis, and improve your knowledge of psoriasis comorbidities and clinical strategies to improve long-term patient outcomes. Dermatologists, physicians, and other health care professionals, including pharmacists, nurses, physician assistants, and nurse practitioners who have an interest in psoriasis are encouraged to participate. Patients with moderate-to-severe psoriasis are at risk for a variety of comorbidities. Dermatologists are in a unique position to screen for these comorbidities and counsel patients to be aware of early symptoms and risk factors. Prevention and early intervention can be achieved by appropriate treatment of psoriasis and reduction of other risk factors contributing to these complications. In this two-part medical simulation, you will meet Lisa, a 45-year-old woman who presents to you feeling very self-conscious about her skin condition, in part one, and has questions about the effects of her skin condition on her overall health, in part two.
For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/04/prweb12637639.htm

Don't be the product, buy the product!

Schweinderl